Longterm efficacy of an antipneumococcal polysaccharide vaccine among patients with autoimmune inflammatory rheumatic diseases

Journal of Rheumatology

Volumn 43, Issue 2, 2016, Pages 267-272

  Broyde, Adi ^a   Arad, Uri ^a   Madar Balakirski, Noa ^a   Paran, Daphna ^a   Kaufman, Ilana ^a   Levartovsky, David ^a   Wigler, Irena ^a   Caspi, Dan ^a   Elkayam, Ori ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Autoimmune Efficacy; Pneumococcal; Rheumatoid Arthritis; Vaccine

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 6 RECEPTOR INHIBITOR; METHOTREXATE; PNEUMOCOCCUS VACCINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ANKYLOSING SPONDYLITIS; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CLINICAL FEATURE; DISEASE DURATION; DRUG EFFICACY; FEMALE; HUMAN; HUMORAL IMMUNITY; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; VACCINATION; AUTOIMMUNE DISEASES; COMPLICATION; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; RHEUMATIC DISEASES; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; AUTOIMMUNE DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RHEUMATIC DISEASES; TREATMENT OUTCOME; VACCINATION; YOUNG ADULT;

EID: 84969373524     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.150397     Document Type: Article

References (40)

1. van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011;70:414-22.
2. Falagas ME, Manta KG, Betsi GI, Pappas G. Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. Clin Rheumatol 2007;26:663-70.
3. Bosch X, Guilabert A, Pallarés L, Cerveral R, Ramos-Casals M, Bovè A, et al. Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. Lupus 2006;15:584-9.
4. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
5. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
6. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al; European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine 2003;82:299-308.
7. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66:940-4.
8. Ruangjutipopan S, Kasitanon N, Louthrenoo W, Sukitawut W, Wichainun R. Causes of death and poor survival prognostic factors in Thai patients with systemic sclerosis. J Med Assoc Thai 2002;85:1204-9.
9. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98.
10. Reinhold-Keller E, Beuge N, Latza U, de Groot K, Rudert H, Nölle B, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000;43:1021-32.
11. Marie I, Hachulla E, Chérin P, Hellot MF, Herson S, Levesque H, et al. Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum 2005;53:155-65.
12. Prevention of pneumococcal disease: recommendations of the Advisory committee on immunization practices (ACIP). MMWR Recomm Rep 1997;46:1-24.
13. Schuchat A, Robinson K, Wenger JD, Harrison LH, Farley M, Reingold AL, et al. Bacterial meningitis in the United States in 1995. Active surveillance team. N Engl J Med 1997;337:970-6.
14. Durand ML, Calderwood SB, Weber DJ, Miller SI, Southwick FS, Caviness VS Jr, et al. Acute bacterial meningitis in adults. A review of 493 episodes. N Engl J Med 1993;328:21-8.
15. de Gans J, van de Beek D; European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002;347:1549-56.
16. Elkayam O, Paran D, Caspi D, Litinsky I, Yaron M, Charboneau D, et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis 2002;34:147-53.
17. Mease PJ, Ritchlin CT, Martin RW, Gottlieb AB, Baumgartner SW, Burge DJ, et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol 2004;31:1356-61.
18. Visvanathan S, Keenan GF, Baker DG, Levinson AI, Wagner CL. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. J Rheumatol 2007;34:952-7.
19. Kapetanovic MC, Saxne T, Sjöholm A, Truedsson L, Jönsson G, Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology 2006;45:106-11.
20. Elkayam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2004;33:283-8.
21. Bingham CO 3rd, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 2010;62:64-74.
22. Mufson MA, Krause HE, Schiffman G, Hughey DF. Pneumococcal antibody levels one decade after immunization of healthy adults. Am J Med Sci 1987;293:279-84.
23. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993;270:1826-31.
24. Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008;1:CD000422.
25. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012;61:816-9.
26. Coulson E, Saravanan V, Hamilton J, So KL, Morgan L, Heycock C, et al. Pneumococcal antibody levels after pneumovax in patients with rheumatoid arthritis on methotrexate. Ann Rheum Dis 2011;70:1289-91.
27. Silman AJ. The 1987 revised American Rheumatism Association criteria for rheumatoid arthritis. Br J Rheumatol 1988;27:341-3.
28. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73.
29. Gofton JP. Report from the subcommittee on diagnostic criteria for ankylosing spondylitis. In: Bennett PH, Wood HN, eds. Population studies of the rheumatic diseases; 1966. New York: Excerpta Medica; 1966:314-6, 456-7.
30. Schauer U, Stemberg F, Rieger CH, Büttner W, Borte M, Schubert S, et al. Levels of antibodies specific to tetanus toxoid, Haemophilus influenzae type b, and pneumococcal capsular polysaccharide in healthy children and adults. Clin Diag Lab Immunol 2003;10:202-7.
31. Musher DM, Manoff SB, Liss C, McFetridge RD, Marchese RD, Bushnell B, et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis 2010;201:516-24.
32. Manoff SB, Liss C, Caulfield MJ, Marchese RD, Silber J, Boslego J, et al. Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged 65 > or = years. J Infect Dis 2010;201:525-33.
33. Valenzuela MT, Altuzarra RH, Trucco OA, Villegas RR, Inostroza JS, Granata PS, et al. Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine in elderly residents of a long-term care facility. Braz J Infect Dis 2007;11:322-6.
34. Brandão AP, de Oliveira TC, de Cunto Brandileone MC, Gonçalves JE, Yara TI, Simonsen V. Persistence of antibody response to pneumococcal capsular polysaccharides in vaccinated long term-care residents in Brazil. Vaccine 2004;23:762-8.
35. Grabenstein JD, Manoff SB. Pneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults. Vaccine 2012;30:4435-44.
36. Dransfield MT, Harnden S, Burton RL, Albert RK, Bailey WC, Casaburi R, et al; NIH COPD Clinical Research Network. Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clin Infect Dis 2012;55:e35-44.
37. Konradsen HB, Rasmussen C, Ejstrud P, Hansen JB. Antibody levels against Streptococcus pneumoniae and Haemophilus influenzae type b in a population of splenectomized individuals with varying vaccination status. Epidemiol Infect 1997;119:167-74.
38. Lindemann M, Heinemann FM, Horn PA, Witzke O. Long-term response to vaccination against pneumococcal antigens in kidney transplant recipients. Transplantation 2012;94:50-6.
39. Kaufman I, Moscovici YB, Abudi Y, Sofer D, Mendelson E, Balbir-Gurman A, et al. The effect of infliximab on antiviral antibody profiles in patients with rheumatoid arthritis. Rheumatol Int 2010;30:325-9.
40. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009;180:48-58.